Overall impact
B (75)

Commentary

IMAC is a strong overall performer. With a 'B' rating of 75.1 for overall impact (89th percentile compared to all companies), IMAC ranks 11th out of 76 industry peers, behind Avedro, AnPac Bio-Medical Science, Planet Innovation and 7 others, and ahead of Enzo Biochem, Invitae, Check-Cap and 62 others. On top material causes for IMAC's industry (Healthcare Software & Services), IMAC performs well in Reduced Waste (87.8 score), Child and Maternal Health (84.7), Improved Mental Health (95.2) and 4 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (34.4 score).
Impact
Cause IMAC
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
154
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Tn, United States
Share classes
IMAC
Description
IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.
Material causes
Ethos considers the following causes material for IMAC, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.